Sameeksha PMS

PMS

IME's View on Sameeksha PMS

AMC View

Sameeksha Capital's credibility is based on founder Bhavin Shah's extensive experience as a top-rated senior analyst at JP Morgan & Credit Suisse, and as head of Equirius Research. With a focus on fundamental research and proprietary tools, Sameeksha Capital is a strong boutique option among PMS firms.

AMC Pedigree

Sameeksha Capital's strong pedigree is founded on founder Bhavin Shah's expertise in fundamental research. The firm has developed robust institutional research processes and proprietary tools to enhance their research capabilities.

Team Pedigree

Bhavin Shah brings a distinguished track record in equity research, having been a top-ranked institutional Asia-Pacific technology analyst at both Credit Suisse and JP Morgan. He also played a pivotal role in building Equirus Securities from the ground up before founding Sameeksha Capital. Known for his strong research pedigree, Bhavin brings deep fundamental research principles and philosophies to Sameeksha’s investment approach.

Investment Philosophy

Sameeksa Capital uses a rigorous fundamental research process, based on Bhavin's extensive experience as a top-rated equity analyst, to identify appealing investment opportunities. They are fairly dynamic in their approach - taking active cash calls & rotating across market capitalisation based on their market view (for example smallcap exposures have moved from as high as 60% in CY23-24 to sub 30% in CY21-22, & they have taken 20%+ cash calls a few times in the past).

AMC Background

Sameeksha Capital was founded in 2015 by Bhavin Shah (a highly acclaimed technology analyst), initially as a vehicle to manage his personal portfolio in a structured environment. It has since been opened to public investors via a PMS platform. Strong Fundamental Research Capabilities Driven by Bhavin Shah Sameeksha Capital pedigree is based on the strong fundamental research pedigree of its founder Bhavin Shah. Bhavin Shah has impeccable equity research credentials, especially in the technology sector where he has won multiple awards.

Investment Philosophy

Bhavin Shah has impeccable fundamental research credentials, which he has used as a foundation to build best-in-class research capabilities and time-tested processes at Sameeksha. Sameeksha's approach constitutes of 4 major factors:
  • Proprietary multi-layered stock selection checklist: Process addresses personal biases and help eliminate weak business models
  • Value vs Quality Matrix: Quality with value discipline on proprietary framework. 
  • Active Sell Framework: Re-evaluation of hold or sell as stocks approach forward price
  • Detailed Financial Models: home grown standardized earnings model providing insights into the quality and the value of the business

Risk Management

  • Sectoral Exposure: <40%
  • Loss Minimisation: Detailed review of the position at -15%. Typically done under normal market conditions after a review that no extraneous factors are affecting the stock price action.

Portfolio Construction

Key Aspects of Portfolio Construction
  • Concentration: Typically 15-30 stock concentrated portfolio based on bottom-up ideas. Large bets on very high conviction ideas. 
  • Cash Position: Flexibility to maintain cash position and partially hedging the portfolio through index futures (if allowed by the client)
  • Investment horizon: >2 years but positions are reviewed periodically
  • Position limit: 20% at cost and no greater than 30% on market value
  • Flexibility: Does not follow a model portfolio approach. Only those stocks below buy level get bought in new accounts.
Rigorous Investment Process Sameeksa Capital follows a strong high quality fundamental research process in order to identify attractive investment opportunities. The research pedigree of its founder Bhavin Shah is Sameeksha's core differentiator, along with their philosophy of tailor making portfolios for investor's based on the best opportunities available at the time of investing as compared to the standard model portfolio approach. Suitable For Investor's wishing to invest in a portfolio backed by strong fundamental research processes.

Investment team

Bhavin Shah | 4-star rated FM

Founder & Fund Manager | 29 yrs Experience | 10 yrs at current firm

Past Experience: Equirius Securities (Founder & CEO), JP Morgan (Head-Asia Pac Tech Research), Credit Suisse (Head-Asia Pac Tech Research)

Bhavin Shah comes with impeccable research credentials, especially in the technology space where he has repeatedly been a top-ranked analyst by Global Institutional Investors. He has also been responsible for building up 3 institutional equity franchises - at Equiris and the technology desks for JP Morgan & Credit Suisse.

Recommended Funds

Sameeksha Equity Fund AIF

1 Year
4.6%
3 Year
31.1%
5 Year
-

Sameeksha Equity

1 Year
1.5%
3 Year
27.2%
5 Year
28.4%
IME Capital Logo

IME Capital is a research-first investments firm. We aim to disrupt the wealth management industry, by shrinking the gap in investment insights between central research teams & RMs/Clients.

Disclaimer MF/PMS/AIF/Direct Equities are all subject to market risks. Please read the scheme information and other related documents carefully prior to investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund or designing a portfolio that suits your needs. Market & other data on this site has been sourced from what are considered to be reliable sources. All views shared (product ratings, views on individual securities etc.) are the proprietary property of IME Capital and cannot be used in any form without explicit written consent. IME Capital Pvt. Ltd. makes no warranties or representations, express or implied, on products offered through the platform (and that of our partners) or on the correctness of data & views shared. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Detailed Disclaimer | © 2021 All rights reserved | ARN No: ARN-182445